Knight Therapeutics Stock Ten Year Return
GUD Stock | CAD 5.37 0.03 0.56% |
Knight Therapeutics fundamentals help investors to digest information that contributes to Knight Therapeutics' financial success or failures. It also enables traders to predict the movement of Knight Stock. The fundamental analysis module provides a way to measure Knight Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Knight Therapeutics stock.
Knight |
Knight Therapeutics Company Ten Year Return Analysis
Knight Therapeutics' Ten Year Return shows the total annualized return generated from holding a fund for the last 10 years and represents fund's capital appreciation, including dividends losses and capital gains distributions. This return indicator is considered by many investors to be the ultimate measures of fund performance and can reflect the overall performance of the market or market segment it invests in.
More About Ten Year Return | All Equity Analysis
Ten Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although Ten Year Fund Return indicator can give a sense of overall fund long-term potential, it is recommended to compare funds performances against other similar funds or market benchmarks for the same 10-year interval.
Competition |
Based on the latest financial disclosure, Knight Therapeutics has a Ten Year Return of 0.0%. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all Canada stocks average (which is currently at 0.0).
Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
All Next | Launch Module |
Knight Fundamentals
Price To Earning | 133.90 X | |||
Revenue | 328.2 M | |||
EBITDA | 56.82 M | |||
Net Income | (16.84 M) | |||
Cash And Equivalents | 302 K | |||
Cash Per Share | 4.10 X | |||
Total Debt | 69.09 M | |||
Debt To Equity | 0.06 % | |||
Current Ratio | 2.31 X | |||
Book Value Per Share | 7.53 X | |||
Cash Flow From Operations | 28.49 M | |||
Earnings Per Share | (0.16) X | |||
Price To Earnings To Growth | 2,857 X | |||
Target Price | 7.19 | |||
Number Of Employees | 725 | |||
Beta | 0.49 | |||
Market Capitalization | 576.83 M | |||
Total Asset | 945.49 M | |||
Retained Earnings | 150.89 M | |||
Working Capital | 251.09 M | |||
Current Asset | 499.48 M | |||
Current Liabilities | 6.74 M | |||
Net Asset | 945.49 M |
About Knight Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Knight Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Knight Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Knight Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Knight Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Knight Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Knight Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Knight Stock
Moving against Knight Stock
0.8 | FFH | Fairfax Financial | PairCorr |
0.77 | FFH-PM | Fairfax Financial | PairCorr |
0.64 | ELF | E L Financial | PairCorr |
0.62 | FFH-PH | Fairfax Financial | PairCorr |
0.6 | FFH-PJ | Fairfax Financial | PairCorr |
The ability to find closely correlated positions to Knight Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Knight Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Knight Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Knight Therapeutics to buy it.
The correlation of Knight Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Knight Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Knight Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Knight Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.